PortalPublikationenCombined 1p/19q loss in oligodendroglial tumors: predictive ...

Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?

Standard

Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? / Weller, Michael; Berger, Hilmar; Hartmann, Christian; Schramm, Johannes; Westphal, Manfred; Simon, Matthias; Goldbrunner, Roland; Krex, Dietmar; Steinbach, Joachim P; Ostertag, Christoph B; Loeffler, Markus; Pietsch, Torsten; von Deimling, Andreas.

in: CLIN CANCER RES, Jahrgang 13, Nr. 23, 23, 2007, S. 6933-6937.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Weller, M, Berger, H, Hartmann, C, Schramm, J, Westphal, M, Simon, M, Goldbrunner, R, Krex, D, Steinbach, JP, Ostertag, CB, Loeffler, M, Pietsch, T & von Deimling, A 2007, 'Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?', CLIN CANCER RES, Jg. 13, Nr. 23, 23, S. 6933-6937. <http://www.ncbi.nlm.nih.gov/pubmed/18056167?dopt=Citation>

APA

Weller, M., Berger, H., Hartmann, C., Schramm, J., Westphal, M., Simon, M., Goldbrunner, R., Krex, D., Steinbach, J. P., Ostertag, C. B., Loeffler, M., Pietsch, T., & von Deimling, A. (2007). Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? CLIN CANCER RES, 13(23), 6933-6937. [23]. http://www.ncbi.nlm.nih.gov/pubmed/18056167?dopt=Citation

Vancouver

Weller M, Berger H, Hartmann C, Schramm J, Westphal M, Simon M et al. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? CLIN CANCER RES. 2007;13(23):6933-6937. 23.

Bibtex

@article{ee172c05b2394d8e84e0b08459f0211a,
title = "Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?",
abstract = "PURPOSE: The combined loss of genetic material on chromosomes 1p and 19q is strongly associated with favorable outcome in patients with WHO grade 3 anaplastic oligodendroglial tumors. The prognostic value of 1p/19q loss in WHO grade 2 oligodendroglial tumors is less well defined. Importantly, the possible effect of combined 1p/19q loss has not been studied in patients who were not treated with radiotherapy or chemotherapy. EXPERIMENTAL DESIGN: Seventy-six patients with oligodendroglioma (n = 33), oligoastrocytoma (n = 30), anaplastic oligodendroglioma (n = 6), or anaplastic oligoastrocytoma (n = 7) were identified who had not received radiotherapy or chemotherapy after their first operation until the end of follow-up or until the first progression and had tissue for 1p/19q status available. 1p/19q status was assessed by multiplex ligation-dependent probe amplification. RESULTS: After a median follow-up of 3.8 years, progressive disease was documented in 34 patients. The estimated median progression-free survival was 4.6 years. Fifty-eight of the 76 patients had a combined loss of 1p and 19q. The absence or presence of combined 1p/19q loss was not prognostic for progression-free survival using multivariate adjustment for histology, extent of resection, and gender. CONCLUSIONS: Combined 1p/19q loss is not a sensitive prognostic biomarker in patients with oligodendroglial tumors who do not receive radiotherapy or chemotherapy. The gene products lost as a consequence of this codeletion may include mediators of resistance to genotoxic therapies. Alternatively, 1p/19q loss might be an early oncogenic lesion promoting the formation of glial neoplasms, which retain high sensitivity to genotoxic stress.",
author = "Michael Weller and Hilmar Berger and Christian Hartmann and Johannes Schramm and Manfred Westphal and Matthias Simon and Roland Goldbrunner and Dietmar Krex and Steinbach, {Joachim P} and Ostertag, {Christoph B} and Markus Loeffler and Torsten Pietsch and {von Deimling}, Andreas",
year = "2007",
language = "Deutsch",
volume = "13",
pages = "6933--6937",
journal = "CLIN CANCER RES",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

RIS

TY - JOUR

T1 - Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?

AU - Weller, Michael

AU - Berger, Hilmar

AU - Hartmann, Christian

AU - Schramm, Johannes

AU - Westphal, Manfred

AU - Simon, Matthias

AU - Goldbrunner, Roland

AU - Krex, Dietmar

AU - Steinbach, Joachim P

AU - Ostertag, Christoph B

AU - Loeffler, Markus

AU - Pietsch, Torsten

AU - von Deimling, Andreas

PY - 2007

Y1 - 2007

N2 - PURPOSE: The combined loss of genetic material on chromosomes 1p and 19q is strongly associated with favorable outcome in patients with WHO grade 3 anaplastic oligodendroglial tumors. The prognostic value of 1p/19q loss in WHO grade 2 oligodendroglial tumors is less well defined. Importantly, the possible effect of combined 1p/19q loss has not been studied in patients who were not treated with radiotherapy or chemotherapy. EXPERIMENTAL DESIGN: Seventy-six patients with oligodendroglioma (n = 33), oligoastrocytoma (n = 30), anaplastic oligodendroglioma (n = 6), or anaplastic oligoastrocytoma (n = 7) were identified who had not received radiotherapy or chemotherapy after their first operation until the end of follow-up or until the first progression and had tissue for 1p/19q status available. 1p/19q status was assessed by multiplex ligation-dependent probe amplification. RESULTS: After a median follow-up of 3.8 years, progressive disease was documented in 34 patients. The estimated median progression-free survival was 4.6 years. Fifty-eight of the 76 patients had a combined loss of 1p and 19q. The absence or presence of combined 1p/19q loss was not prognostic for progression-free survival using multivariate adjustment for histology, extent of resection, and gender. CONCLUSIONS: Combined 1p/19q loss is not a sensitive prognostic biomarker in patients with oligodendroglial tumors who do not receive radiotherapy or chemotherapy. The gene products lost as a consequence of this codeletion may include mediators of resistance to genotoxic therapies. Alternatively, 1p/19q loss might be an early oncogenic lesion promoting the formation of glial neoplasms, which retain high sensitivity to genotoxic stress.

AB - PURPOSE: The combined loss of genetic material on chromosomes 1p and 19q is strongly associated with favorable outcome in patients with WHO grade 3 anaplastic oligodendroglial tumors. The prognostic value of 1p/19q loss in WHO grade 2 oligodendroglial tumors is less well defined. Importantly, the possible effect of combined 1p/19q loss has not been studied in patients who were not treated with radiotherapy or chemotherapy. EXPERIMENTAL DESIGN: Seventy-six patients with oligodendroglioma (n = 33), oligoastrocytoma (n = 30), anaplastic oligodendroglioma (n = 6), or anaplastic oligoastrocytoma (n = 7) were identified who had not received radiotherapy or chemotherapy after their first operation until the end of follow-up or until the first progression and had tissue for 1p/19q status available. 1p/19q status was assessed by multiplex ligation-dependent probe amplification. RESULTS: After a median follow-up of 3.8 years, progressive disease was documented in 34 patients. The estimated median progression-free survival was 4.6 years. Fifty-eight of the 76 patients had a combined loss of 1p and 19q. The absence or presence of combined 1p/19q loss was not prognostic for progression-free survival using multivariate adjustment for histology, extent of resection, and gender. CONCLUSIONS: Combined 1p/19q loss is not a sensitive prognostic biomarker in patients with oligodendroglial tumors who do not receive radiotherapy or chemotherapy. The gene products lost as a consequence of this codeletion may include mediators of resistance to genotoxic therapies. Alternatively, 1p/19q loss might be an early oncogenic lesion promoting the formation of glial neoplasms, which retain high sensitivity to genotoxic stress.

M3 - SCORING: Zeitschriftenaufsatz

VL - 13

SP - 6933

EP - 6937

JO - CLIN CANCER RES

JF - CLIN CANCER RES

SN - 1078-0432

IS - 23

M1 - 23

ER -